Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Jennifer R. Brown, MD, PhD


Medical Oncology

Make an Appointment
Watch Video

Jennifer R. Brown, MD, PhD americas top doctors

Physician

  • Director, Chronic Lymphocytic Leukemia (CLL) Center
  • Institute Physician
  • Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology, Harvard Medical School

Centers/Programs

Clinical Interests

  • Chronic lymphocytic leukemia
  • Lymphoma
  • Stem cell/bone marrow transplant

Diseases Treated

  • Leukemia, Chronic Lymphocytic (CLL)

Contact Information

  • Appointments617-632-6246 (new)
    617-632-5847 (follow-up)
  • Office Phone Number617-632-5847
  • Fax617-582-7890

Bio

Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction. She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize. She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at DFCI. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL.

Her interests include the development of novel targeted therapeutics for CLL, as well as CLL genomics. She has been instrumental in the clinical development of idelalisib and ibrutinib, leading to their regulatory approvals in CLL. Her genomics work has characterized the somatic mutation profile of CLL, and she is now particularly interested in the implementation of genomic technology in the clinic. She also has a longstanding research interest in the inherited predisposition to CLL. To date she has published about 250 papers in the scientific literature, predominantly in CLL. In 2014 she was the recipient of two awards from DFCI, the Clinical Innovation Award, as well as the George Canellos Award. She is a member of the International Workshop on CLL (iwCLL) and enjoys a worldwide reputation as a CLL expert having made the Highly Cited Researchers list by Clarivate, with multiple papers ranking in the top 1% by citations for their field and year of publication.

Board Certification:

  • Hematology, 2004
  • Internal Medicine, 2001
  • Medical Oncology, 2004

Fellowship:

  • Dana-Farber/Partners CancerCare, Medical Oncology

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Research

Novel therapeutics in CLL Familial Predisposition to CLL and lymphoma

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. J Clin Oncol. 2022 Nov 17; JCO2200510.
View in: PubMed

Resistance to PI3Kd inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. Haematologica. 2022 11 01; 107(11):2685-2697.
View in: PubMed

Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia. J Clin Oncol. 2022 Oct 31; JCO2200269.
View in: PubMed

Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance. Blood Adv. 2022 Oct 26.
View in: PubMed

Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2022 Oct 14; 28(20):4444-4455.
View in: PubMed

EXABS-179-CLL DEBATE: Sequencing Small Molecules Is the Way to Go. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S81-S82.
View in: PubMed

Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022 Nov; 54(11):1664-1674.
View in: PubMed

PI3K inhibitors in haematological malignancies. Lancet Oncol. 2022 08; 23(8):e364.
View in: PubMed

PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? Haematologica. 2022 Jul 28.
View in: PubMed

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:897280.
View in: PubMed

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 08; 23(8):1031-1043.
View in: PubMed

Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients". Haematologica. 2022 06 01; 107(6):1491-1492.
View in: PubMed

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022 06 01; 107(6):1335-1346.
View in: PubMed

Idelalisib activates AKT via increased recruitment of PI3Kd/PI3Kß to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022 07; 36(7):1806-1817.
View in: PubMed

Editorial: Targeting Bruton Tyrosine Kinase. Front Cell Dev Biol. 2022; 10:909655.
View in: PubMed

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May; 9(5):e327-e339.
View in: PubMed

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022 04 01; 107(4):984-987.
View in: PubMed

Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia. Br J Haematol. 2022 04; 197(2):207-211.
View in: PubMed

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 02 15; 28(4):603-608.
View in: PubMed

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022 02 03; 139(5):686-689.
View in: PubMed

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222.
View in: PubMed

Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 12 01; 11(12):3048-3063.
View in: PubMed

Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors. Front Immunol. 2021; 12:804735.
View in: PubMed

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front Oncol. 2021; 11:720704.
View in: PubMed

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 2022 03; 36(3):723-732.
View in: PubMed

Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol. 2021 Dec; 8(12):e912-e921.
View in: PubMed

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kd inhibitor idelalisib. Haematologica. 2021 11 01; 106(11):2995-2999.
View in: PubMed

Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Res. 2021 12 15; 81(24):6117-6130.
View in: PubMed

Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10.
View in: PubMed

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402.
View in: PubMed

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. Blood Adv. 2021 08 24; 5(16):3062-3065.
View in: PubMed

The future of antibody therapy in chronic lymphocytic leukemia. Expert Opin Emerg Drugs. 2021 09; 26(3):323-336.
View in: PubMed

Idelalisib immune-related toxicity is associated with improved treatment response. Leuk Lymphoma. 2021 12; 62(12):2915-2920.
View in: PubMed

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 10; 35(10):2854-2861.
View in: PubMed

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood. 2021 07 08; 138(1):44-56.
View in: PubMed

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021 11; 35(11):3059-3072.
View in: PubMed

Targeting Bruton's Tyrosine Kinase in CLL. Front Immunol. 2021; 12:687458.
View in: PubMed

Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021 06 17; 137(24):3327-3338.
View in: PubMed

The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am. 2021 08; 35(4):807-826.
View in: PubMed

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. Front Oncol. 2021; 11:640731.
View in: PubMed

Chronic Lymphocytic Leukemia: So Much Progress, Still Challenges Ahead. Hematol Oncol Clin North Am. 2021 08; 35(4):xiii-xiv.
View in: PubMed

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. Blood. 2021 05 06; 137(18):2481-2494.
View in: PubMed

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021 11; 35(11):3201-3211.
View in: PubMed

Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential. Front Cell Dev Biol. 2021; 9:648925.
View in: PubMed

High-grade heart block associated with ibrutinib therapy. HeartRhythm Case Rep. 2021 Jun; 7(6):391-394.
View in: PubMed

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021 08; 39(4):1099-1105.
View in: PubMed

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
View in: PubMed

AKT: a key to RT? Blood. 2021 02 04; 137(5):582-584.
View in: PubMed

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98.
View in: PubMed

Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature. 2021 02; 590(7844):157-162.
View in: PubMed

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020 12 17; 136(25):2918-2926.
View in: PubMed

Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 01; 2(1):54-69.
View in: PubMed

A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
View in: PubMed

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica. 2020 10 13; 106(9):2354-2363.
View in: PubMed

Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
View in: PubMed

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
View in: PubMed

Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 09 03; 136(10):1134-1143.
View in: PubMed

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989.
View in: PubMed

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia. 2021 04; 35(4):1064-1072.
View in: PubMed

How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. Hemasphere. 2020 Aug; 4(4):e432.
View in: PubMed

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. Leukemia. 2020 12; 34(12):3404-3407.
View in: PubMed

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv. 2020 04 14; 4(7):1458-1463.
View in: PubMed

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020 04 09; 135(15):1204-1213.
View in: PubMed

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020 Apr; 16(10):517-523.
View in: PubMed

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
View in: PubMed

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32.
View in: PubMed

Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy? J Natl Compr Canc Netw. 2019 11; 17(11.5):1408-1410.
View in: PubMed

Phosphatidylinositol 3 Kinase d Inhibitors: Present and Future. Cancer J. 2019 Nov/Dec; 25(6):394-400.
View in: PubMed

Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. Mycoses. 2019 Dec; 62(12):1140-1147.
View in: PubMed

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 12; 94(12):1353-1363.
View in: PubMed

Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019 10 01; 74(13):1667-1678.
View in: PubMed

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
View in: PubMed

For CLL cells, there's no place like home. Leuk Lymphoma. 2019 12; 60(14):3347-3349.
View in: PubMed

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6.
View in: PubMed

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 08 22; 134(8):688-698.
View in: PubMed

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155.
View in: PubMed

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428.
View in: PubMed

Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479.
View in: PubMed

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019 05 14; 3(9):1553-1562.
View in: PubMed

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(12):2931-2938.
View in: PubMed

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174.
View in: PubMed

Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). Leuk Lymphoma. 2019 10; 60(10):2580-2583.
View in: PubMed

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562.
View in: PubMed

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 05 09; 133(19):2031-2042.
View in: PubMed

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood. 2019 02 28; 133(9):990-992.
View in: PubMed

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019 Jan; 6(1):e38-e47.
View in: PubMed

MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. Br J Haematol. 2019 03; 184(6):925-936.
View in: PubMed

Ibrutinib: searching for a partner drug. Lancet Oncol. 2019 01; 20(1):3-5.
View in: PubMed

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 02; 184(4):558-569.
View in: PubMed

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528.
View in: PubMed

Relapsed CLL: sequencing, combinations, and novel agents. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):248-255.
View in: PubMed

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell. 2018 12 10; 34(6):982-995.e7.
View in: PubMed

PI3K p110d inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. J Clin Invest. 2019 01 02; 129(1):122-136.
View in: PubMed

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leuk Lymphoma. 2019 05; 60(5):1312-1315.
View in: PubMed

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 12; 18(12):803-813.e7.
View in: PubMed

Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware. Leuk Lymphoma. 2018 12; 59(12):2767-2768.
View in: PubMed

Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia? Haematologica. 2018 07; 103(7):1096-1098.
View in: PubMed

Ibrutinib: coming of age? Blood. 2018 04 26; 131(17):1880-1882.
View in: PubMed

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematol. 2018 Apr; 5(4):e170-e180.
View in: PubMed

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One. 2018; 13(3):e0193249.
View in: PubMed

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018 03; 11(3):185-194.
View in: PubMed

Enhanced activation and expansion of T cells using mechanically soft elastomer fibers. Adv Biosyst. 2018 Feb; 2(2).
View in: PubMed

How I treat CLL patients with ibrutinib. Blood. 2018 01 25; 131(4):379-386.
View in: PubMed

The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. Oncologist. 2018 03; 23(3):288-296.
View in: PubMed

Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. Ther Adv Hematol. 2018 Jan; 9(1):3-19.
View in: PubMed

Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Leuk Lymphoma. 2018 08; 59(8):1986-1989.
View in: PubMed

Reply to S. Opat et al. J Clin Oncol. 2017 12 20; 35(36):4094-4095.
View in: PubMed

Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood. 2017 11 30; 130(22):2443-2444.
View in: PubMed

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL. Blood. 2017 11 23; 130(21):2278-2282.
View in: PubMed

PI3Kd-selective and PI3Ka/d-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2017 Nov; 26(11):1267-1279.
View in: PubMed

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Curr Oncol Rep. 2017 Sep; 19(9):61.
View in: PubMed

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 10; 102(10):1796-1805.
View in: PubMed

Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017 09 10; 35(26):2989-2992.
View in: PubMed

Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose? Expert Rev Hematol. 2017 08; 10(8):707-718.
View in: PubMed

Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res. 2017 08; 27(8):1300-1311.
View in: PubMed

Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Drugs Aging. 2017 07; 34(7):509-527.
View in: PubMed

Changes in Bcl-2 Family Protein Profile During Idelalisib Therapy Mimic Those During Duvelisib Therapy in Chronic Lymphocytic Leukemia Lymphocytes. JCO Precis Oncol. 2017; 1.
View in: PubMed

The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Oct; 58(10):2287-2297.
View in: PubMed

Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May; 26(5):633-650.
View in: PubMed

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 05 11; 129(19):2612-2615.
View in: PubMed

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar; 4(3):e114-e126.
View in: PubMed

Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017 05 04; 129(18):2581-2584.
View in: PubMed

Phosphatidylinositol 3-kinase d blockade increases genomic instability in B cells. Nature. 2017 02 23; 542(7642):489-493.
View in: PubMed

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 03; 18(3):297-311.
View in: PubMed

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940.
View in: PubMed

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763.
View in: PubMed

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 12 22; 128(25):2899-2908.
View in: PubMed

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31.
View in: PubMed

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016 12; 22(12):2117-2125.
View in: PubMed

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct; 17(10):1409-1418.
View in: PubMed

Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. 2016 Aug 16; 7(33):53515-53525.
View in: PubMed

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clin Cancer Res. 2017 Feb 01; 23(3):735-745.
View in: PubMed

Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-d/? Inhibitors. ACS Med Chem Lett. 2016 Oct 13; 7(10):908-912.
View in: PubMed

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13.
View in: PubMed

FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. Am J Hematol. 2016 10; 91(10):978-83.
View in: PubMed

A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. Br J Haematol. 2017 09; 178(5):820-823.
View in: PubMed

Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. 2016 May 31; 7(22):32641-51.
View in: PubMed

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
View in: PubMed

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 2016 07 28; 128(4):574-83.
View in: PubMed

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.
View in: PubMed

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8.
View in: PubMed

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
View in: PubMed

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016 06 23; 127(25):3215-24.
View in: PubMed

Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. MAbs. 2016 May-Jun; 8(4):787-98.
View in: PubMed

Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606.
View in: PubMed

The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Semin Oncol. 2016 Apr; 43(2):260-4.
View in: PubMed

A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95.
View in: PubMed

Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? Am Soc Clin Oncol Educ Book. 2016; 35:e387-98.
View in: PubMed

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
View in: PubMed

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):323-32.
View in: PubMed

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22.
View in: PubMed

Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS One. 2015; 10(11):e0143685.
View in: PubMed

Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. BMJ Open. 2015 Oct 06; 5(10):e008350.
View in: PubMed

A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):694-8.
View in: PubMed

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42.
View in: PubMed

The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target. Leuk Lymphoma. 2015; 56(10):2755-6.
View in: PubMed

Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy. Oncology (Williston Park). 2015 Jun; 29(6):442, 444.
View in: PubMed

Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. Br J Haematol. 2015 Sep; 170(5):694-703.
View in: PubMed

Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015; 56(10):2779-86.
View in: PubMed

Targeting neddylation effectively antagonizes nuclear factor-?B in chronic lymphocytic leukemia B-cells. Leuk Lymphoma. 2015 May; 56(5):1566-9.
View in: PubMed

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clin Cancer Res. 2015 Jul 15; 21(14):3160-9.
View in: PubMed

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30; 125(18):2779-85.
View in: PubMed

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 07; 125(19):2915-22.
View in: PubMed

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; 39(5):495-500.
View in: PubMed

Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 2015 Feb; 75(2):143-55.
View in: PubMed

Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014 Dec 08; 26(6):813-825.
View in: PubMed

Idelalisib for chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014 Dec; 12(12):846-8.
View in: PubMed

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1878-80.
View in: PubMed

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma. 2015 Apr; 56(4):993-8.
View in: PubMed

A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol. 2014 Oct; 167(2):149-61.
View in: PubMed

Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma. PLoS One. 2014; 9(7):e101685.
View in: PubMed

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31; 511(7511):616-20.
View in: PubMed

Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA7008.
View in: PubMed

Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population. J Card Fail. 2014 Aug; 20(8):555-9.
View in: PubMed

Chronic lymphocytic leukemia: moving forward-rapidly. Semin Hematol. 2014 Jul; 51(3):157.
View in: PubMed

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17; 371(3):213-23.
View in: PubMed

Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1390-8.
View in: PubMed

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 03; 124(1):42-8.
View in: PubMed

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 01; 32(19):2067-73.
View in: PubMed

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May; 10(6):957-67.
View in: PubMed

Somatic mutation as a mechanism of Wnt/ß-catenin pathway activation in CLL. Blood. 2014 Aug 14; 124(7):1089-98.
View in: PubMed

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91.
View in: PubMed

The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-?B activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014 Mar 15; 20(6):1576-89.
View in: PubMed

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29; 123(22):3406-13.
View in: PubMed

A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014 May 29; 123(22):3398-405.
View in: PubMed

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29; 123(22):3390-7.
View in: PubMed

Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014 Mar; 150(3):280-7.
View in: PubMed

B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. Immunotargets Ther. 2014; 3:29-38.
View in: PubMed

Novel treatments for chronic lymphocytic leukemia and moving forward. Am Soc Clin Oncol Educ Book. 2014; e317-25.
View in: PubMed

A new era of treatment for chronic lymphocytic leukaemia? Lancet Oncol. 2014 Jan; 15(1):3-5.
View in: PubMed

Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transplant. 2014 Mar; 20(3):421-4.
View in: PubMed

Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Apr; 55(4):920-8.
View in: PubMed

End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77.
View in: PubMed

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
View in: PubMed

Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future. Ther Adv Hematol. 2013 Aug; 4(4):298-308.
View in: PubMed

Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6.
View in: PubMed

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma. 2014 Feb; 55(2):263-9.
View in: PubMed

B-cell receptor inhibitors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2013 Jun; 11(6):362-4.
View in: PubMed

Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013 Aug; 54(8):1823-5.
View in: PubMed

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70.
View in: PubMed

Genomic approaches to chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2013 Apr; 27(2):157-71.
View in: PubMed

Hematology/Oncology Clinics of North America. Chronic Lymphocytic Leukemia. Preface. Hematol Oncol Clin North Am. 2013 Apr; 27(2):xiii-xiv.
View in: PubMed

Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2013 Apr; 27(2):329-39.
View in: PubMed

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013 Mar; 8(1):1-6.
View in: PubMed

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
View in: PubMed

Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma. 2013 Sep; 54(9):1915-20.
View in: PubMed

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8.
View in: PubMed

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17.
View in: PubMed

Gastric mucosa-associated lymphoid tissue lymphoma resistant to Helicobacter pylori eradication: what's the best option? Leuk Lymphoma. 2013 May; 54(5):899-900.
View in: PubMed

Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett. 2012 Dec 12; 12(12):6498-504.
View in: PubMed

Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Dec; 53(12):2362-70.
View in: PubMed

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9.
View in: PubMed

Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9.
View in: PubMed

LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1678-86.
View in: PubMed

BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012 Aug 15; 72(16):4193-203.
View in: PubMed

Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jul 15; 18(14):3791-802.
View in: PubMed

Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol. 2012 Apr 01; 30(10):1072-9.
View in: PubMed

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6.
View in: PubMed

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10; 30(5):488-96.
View in: PubMed

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
View in: PubMed

rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res. 2011 Nov 01; 17(21):6702-11.
View in: PubMed

Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med. 2011 Jun 07; 154(11):727-36.
View in: PubMed

Insulin receptor activation in deletion 11q chronic lymphocytic leukemia. Clin Cancer Res. 2011 May 01; 17(9):2605-7.
View in: PubMed

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011 May 01; 17(9):2977-86.
View in: PubMed

MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 2011 Mar 08; 6(3):e16956.
View in: PubMed

Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 2011 Mar 15; 71(6):2298-307.
View in: PubMed

Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected]. Hematology Am Soc Hematol Educ Program. 2011; 2011:119-20.
View in: PubMed

The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:110-8.
View in: PubMed

Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8.
View in: PubMed

Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec; 203(2):134-40.
View in: PubMed

Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2010 Dec; 8(12):886-95.
View in: PubMed

Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer. 2011 Apr 01; 117(7):1470-7.
View in: PubMed

Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10(5):369-78.
View in: PubMed

Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol. 2010 Dec; 38(12):1167-77.
View in: PubMed

Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov; 151(4):336-45.
View in: PubMed

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24.
View in: PubMed

Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong? Leuk Lymphoma. 2010 Aug; 51(8):1382-5.
View in: PubMed

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in: PubMed

ASCT in follicular lymphoma. Nat Rev Clin Oncol. 2009 Jul; 6(7):380-2.
View in: PubMed

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8.
View in: PubMed

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74.
View in: PubMed

Inherited predisposition to chronic lymphocytic leukemia. Expert Rev Hematol. 2008 Oct; 1(1):51-61.
View in: PubMed

Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008 Nov; 143(3):361-8.
View in: PubMed

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1923-30.
View in: PubMed

Pseudohyperkalemia in chronic lymphocytic leukemia. J Clin Oncol. 2008 Jun 01; 26(16):2781-2.
View in: PubMed

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25.
View in: PubMed

Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15; 111(10):5101-8.
View in: PubMed

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203.
View in: PubMed

Pseudohyperkalemia in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 2008; In Press..

AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter. J Clin Oncol. 2007 Jul 20; 25(21):3176-8.
View in: PubMed

Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1057-65.
View in: PubMed

Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL). Blood. 2007; 110:951a.

TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP70. Blood. 2007; 110:616a.

A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL). Blood. 2007; 110:920a.

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas. Blood. 2007; 110:408a.

Interim Safety and Efficacy Results from the Phase 2 Multicenter Study of Subcutaneous Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-cell CLL. Leukemia and Lymphoma. 2007; 48(Suppl 1):S175.

Richter's Transformation: Pathobiology and Treatment. In: UpToDate, Rose, B.D., Ed. 2007.

Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L. Blood. 2007; 110:227a.

Prevalence of Familial Malignancy in a Prospectively Screened Cohort of Patients with CLL and Lymphoproliferative Disorders. Leukemia and Lymphoma. 2007; 48(Suppl 1):S141.

AIDS-Associated Plasmablastic Lymphoma Presenting at the Insertion Site of a Peritoneal Dialysis Catheter. Journal of Clinical Oncology. 2007; 25:3176-3178.

Relative Value of ZAP70, CD38 and Immunoglobulin Mutation Status in Predicting Disease Progression in Chronic Lymphocytic Leukemia. Leukemia and Lymphoma. 2007; 48(Suppl 1):S90.

Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma. Blood. 2007; 110:689a.

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. Blood. 2007; 110:4496a.

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007 Jan; 117(1):112-21.
View in: PubMed

Systematic Genomic Screen for Tyrosine Kinase Mutations in CLL. Blood. 2007; 110:616a.

Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia. Blood. 2006; 108(11):786a.

Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study. Blood. 2006; 108(11):336b.

Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse. Blood. 2006; 108(11):865a.

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression. Blood. 2006; 108(11):785a.

Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter’s Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia. Blood. 2006; 108(11):799a.

Prevalence of Familial Lymphoproliferative Malignancy in a Prospectively Screened Cohort of Patients with Lymphoproliferative Disorders. Blood. 2006; 108(11):246a.

Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients with CLL. Blood. 2006; 108(11):804a.

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64.
View in: PubMed

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen. Journal of Clinical Oncology. 2006; 24(18S):6598.

Differential Diagnosis. Canellos GP, Lister AT, Young B, Eds. The Lymphomas. 2006; 158-66.

Paraneoplastic Syndromes. Canellos GP, Lister AT, Young B, Eds. The Lymphomas. 2006; 139-46.

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen. Blood. 2005; 106(11):601a.

Paradoxical embolism after peripheral blood stem cell infusion. Bone Marrow Transplant. 2005 Sep; 36(6):561-2.
View in: PubMed

Chronic lymphocytic leukemia: a niche for flavopiridol? Clin Cancer Res. 2005 Jun 01; 11(11):3971-3.
View in: PubMed

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005 Apr 01; 23(10):2208-14.
View in: PubMed

Pathobiology of the Aggressive and Highly Aggressive Non Hodgkin’s Lymphomas. In: UpToDate, Rose, B.D. Ed. 2005.

Pathobiology of the Indolent Non Hodgkin’s Lymphomas. In: UpToDate, Rose, B.D. Ed. 2005.

Secondary Solid Tumors after Autologous Bone Marrow Transplantation for Non-Hodgkin’s Lymphoma. American Journal of Oncology Review. 2005; 4:530-3.

Pathobiology of T Cell Non Hodgkin’s Lymphomas. In: UpToDate, Rose, B.D. Ed. 2005.

Unusual sites of Hodgkin's lymphoma: CASE 2. Hodgkin's lymphoma of the CNS masquerading as meningioma. J Clin Oncol. 2004 Oct 15; 22(20):4228-30.
View in: PubMed

Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. Am J Clin Pathol. 2004 May; 121(5):701-8.
View in: PubMed

Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma. 2004 Feb; 45(2):315-20.
View in: PubMed

Clinical mimics of lymphoma. Oncologist. 2004; 9(4):406-16.
View in: PubMed

Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. J Clin Oncol. 2003 Jun 15; 21(12):2437-8.
View in: PubMed

Castleman’s Disease. In: UpToDate, Rose, B.D. Ed. 2003.

Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep. 2002 Nov; 1(2):110-8.
View in: PubMed

Anticoagulation. Basch EM, Birnbaum SL, Garza C, Messersmith W, editors. The MGH Primer of Outpatient Medicine. 2002; 241-6.

Anemia. Basch EM, Birnbaum SL, Garza C, Messersmith W, editors. The MGH Primer of Outpatient Medicine. 2002; 235-40.

The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Thromb Haemost. 2001 Jun; 85(6):979-85.
View in: PubMed

Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures. J Neurosci. 1998 Sep 01; 18(17):6952-62.
View in: PubMed

Fos family members induce cell cycle entry by activating cyclin D1. Mol Cell Biol. 1998 Sep; 18(9):5609-19.
View in: PubMed

FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci U S A. 1997 Sep 16; 94(19):10397-402.
View in: PubMed

A defect in nurturing in mice lacking the immediate early gene fosB. Cell. 1996 Jul 26; 86(2):297-309.
View in: PubMed

The Role of Fos Family Genes in Adaptive Neuronal Responses and Cell Proliferation [PhD Dissertation]. 1996.

A cell culture model system for genetic analyses of the cell cycle by targeted homologous recombination. Oncogene. 1993 Apr; 8(4):899-907.
View in: PubMed

Gene Targeting of the c-Raf Proto-Oncogene [Master's Thesis]. 1990.

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top